The application effect of neoadjuvant chemotherapy combined with breast conserving surgery and modified radical surgery in the treatment of stage Ⅱ and Ⅲ breast cancer respectively

doi:10.3877/cma.j.issn.1674-3946.2025.02.018.

Abstract

Abstract:

Objective

To explore the effect of neoadjuvant chemotherapy combined with breast conserving surgery and modified radical surgery in the treatment of stage Ⅱ and Ⅲ breast cancer respectively.

Methods

Clinical data of 99 patients with breast cancer admitted from January 2017 to December 2019 were retrospectively analyzed, and divided into control group (neoadjuvant chemotherapy combined with modified radical surgery, n=49 cases) and observation group (neoadjuvant chemotherapy combined with breastconserving surgery, n=50 cases) according to different treatment methods.SPSS 25.0 software was used to process the data.Perioperative indicators, serum tumor markers and other measurement data were expressed as(x±s), and independent sample t test was used.The incidence of postoperative complications and recurrence survival were analyzed by Chi-square test.P＜0.05 was considered statistically significant.

Results

There was no significant difference in operation time between the two groups (P＞0.05).The duration of hospitalization and drainage tube removal in observation group was shorter than that in control group, and the amount of intraoperative blood loss was lower than that in control group (P＜0.05).The levels of carbohydrate antigen (CA)125 and carcinoembryonic antigen (CEA) in 2 groups were decreased after surgery, but there was no statistical significance between groups (P＞0.05).The total incidence of postoperative complications in observation group (4.0%) was lower than that in control group (18.4%), and the difference was statistically significant(P＜0.05).There was no significant difference in recurrence rate and survival rate between observation group and control group within 3 years after operation (P＞0.05).

Conclusion

Compared with modified radical surgery, breast-conserving surgery has a similar therapeutic effect for breast cancer patients, but the latter has less intraoperative blood loss, shorter hospitalization and drainage tube removal time, and a lower incidence of postoperative complications.

Key words: Breast Cancer, Modified Radical Mastectomy, Breast Conserving Surgery, Neoadjuvant Chemotherapy

Youxin He, Linhui Han, Heqing Yang. The application effect of neoadjuvant chemotherapy combined with breast conserving surgery and modified radical surgery in the treatment of stage Ⅱ and Ⅲ breast cancer respectively[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(02): 184-187.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhpwkssxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3946.2025.02.018.

https://zhpwkssxzz.cma-cmc.com.cn/EN/Y2025/V19/I02/184

Figures/Tables 5

组别	例数	年龄（岁， $\overset{ˉ}{x}$ ±s）	BMI（kg/m²， $\overset{ˉ}{x}$ ±s）	TNM分期（例）	病灶位置（例）	化疗周期（例）
组别	例数	年龄（岁， $\overset{ˉ}{x}$ ±s）	BMI（kg/m²， $\overset{ˉ}{x}$ ±s）	Ⅱ/Ⅲ	左侧/右侧	2个/3个
观察组	50	44.3±6.6	23.5±2.5	21/19	26/24	30/20
对照组	49	45.0±10.7	23.2±2.2	28/21	27/22	26/23
t/χ²值		0.409	0.562	0.192	0.096	0.485
P值		0.684	0.576	0.661	0.757	0.486

组别	例数	年龄（岁， $\overset{ˉ}{x}$ ±s）	BMI（kg/m²， $\overset{ˉ}{x}$ ±s）	TNM分期（例）	病灶位置（例）	化疗周期（例）
组别	例数	年龄（岁， $\overset{ˉ}{x}$ ±s）	BMI（kg/m²， $\overset{ˉ}{x}$ ±s）	Ⅱ/Ⅲ	左侧/右侧	2个/3个
观察组	50	44.3±6.6	23.5±2.5	21/19	26/24	30/20
对照组	49	45.0±10.7	23.2±2.2	28/21	27/22	26/23
t/χ²值		0.409	0.562	0.192	0.096	0.485
P值		0.684	0.576	0.661	0.757	0.486

组别	例数	手术时间（min）	拔除引流管时间（d）	住院时间（d）	术中出血量（ml）
观察组	29	85.3±11.7	4.5±1.3	8.8±2.2	225.4±24.5
对照组	32	83.6±12.3	7.0±2.0	12.8±3.1	339.7±32.9
t值		0.699	7.570	7.294	19.644
P值		0.486	＜0.001	＜0.001	0.001

组别	例数	CA125（U/L）		CEA（ng/L）
组别	例数	术前	术后	术前	术后
观察组	50	15.2±4.3	9.1±3.2^a	7.6±2.3	4.3±1.8^a
对照组	49	15.0±4.4	9.2±3.56^a	7.7±2.3	4.2±1.5^a
t值		0.219	0.176	0.196	0.329
P值		0.827	0.861	0.845	0.743

组别	例数	患侧上肢水肿	皮下积液	皮瓣坏死	感染	总并发症
观察组	50	1（2.0）	1（2.0）	0（0.0）	0（0.0）	2（4.0）
对照组	49	3（6.1）	2（4.1）	1（2.0）	3（6.1）	9（18.4）
χ ²值		-	-	-	-	5.172
P值		-	-	-	-	0.023

组别	例数	术后3年内复发情况	术后3年内生存情况
观察组	50	2（4.0）	4（8.0）
对照组	49	3（6.1）	5（10.2）
χ ²值		0.001	0.001
P值		0.982	0.975

References 16

［1］	孙曼迪, 符德元.评估应用术前PLR,NLR及AGR预测乳腺癌患者预后的价值［J/CD］.中华普外科手术学杂志(电子版),2022, 16(02): 137-141.
［2］	王小为, 雷海, 余书蓉, 等.乳腺癌患者术后远处转移及其不良结局的危险因素［J/CD］.中华普外科手术学杂志(电子版),2022, 16(2): 162-165.
［3］	Jagsi R,Mason G,Overmoyer BA,et al.Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research ［J］.Breast Cancer Res Treat,2022,192(2): 235-243.
［4］	袁忠, 马海南, 王科军.改良根治术与保乳手术对早期乳腺癌的临床效果,术后并发症及生活质量的影响分析［J］.湖南师范大学学报: 医学版, 2022, 19(04): 91-94.
［5］	朱先超, 陈浩浩, 曹鋆.保乳术和改良根治术治疗乳腺癌的安全性及有效性对照研究［J］.武警后勤学院学报: 医学版,2021, 30(08): 177-178.
［6］	王晓娇, 练孝春, 韩涛, 等.新辅助化疗联合保乳术对早期乳腺癌患者的临床运用分析［J］.河北医学, 2022, 28(11):1887-1891.
［7］	中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2015版) ［J］.中国癌症杂志, 2015, 25(09):692-754.
［8］	焦诚, 崔兴尧, 刘伟.乳腺癌新辅助化疗后行前哨淋巴结活检的研究进展［J］.解放军医药杂志, 2022, 34(04): 112-116.
［9］	陈彦超, 舒文政, 汤培政.新辅助化疗联合手术治疗骨肉瘤的临床疗效及对预后的影响［J］.癌症进展, 2023, 21(06):628-631.
［10］	谢新美, 闭月琼, 吴斯敏, 等.局部晚期乳腺癌新辅助化疗联合保乳手术治疗的临床疗效观察［J］.广西医科大学学报,2022, 39(06): 959-962.
［11］	徐炜炜, 张红英.术前新辅助化疗联合肿瘤细胞减灭术治疗卵巢癌的疗效观察［J］.中国肿瘤临床与康复, 2022, 29(08):897-901.
［12］	梁欣, 刘维, 荆海红.早期乳腺癌患者改良根治术与保乳手术治疗的效果及对患者术后生活质量的影响［J］.实用癌症杂志, 2021, 36(05): 793-795.
［13］	彭永强, 刘建军, 王平, 等.保乳术与改良乳腺癌根治术对早期乳腺癌患者的生活质量及预后影响对比［J］.中国临床医生杂志, 2023, 51(04): 458-461.
［14］	沈钧华, 包小平, 马元勇, 等.前哨淋巴结活检联合保乳术与根治术治疗乳腺癌的临床疗效观察［J］.山西医药杂志, 2021,50(03): 433-435.
［15］	谢景军, 张建峰, 孙常青, 等.新辅助化疗联合保乳术治疗乳腺癌的疗效观察［J］.中国肿瘤临床与康复, 2021, 28(03):290-293
［16］	吴炅, 修秉虬, 张琪.乳腺癌保乳手术与重建策略［J］.中国实用外科杂志, 2021, 41(11): 1213-1216.

[1]	Quanyu Nie, Mingxing Li, Ying Liu, Hui Wang, Yuanyuan Chen, Hong Zhou, Yang Zhou. Ultrasound-based intratumoral and peritumoral radiomics for predicting HER2 status in patients with breast cancer [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2024, 21(12): 1103-1110.
[2]	Wei Hong, Xirong Ye, Zhihong Liu, Yinfeng Yang, Zhihong Lyu. Value of ultrasound radiomics combined with clinicopathological features in predicting complete pathological response to neoadjuvant chemotherapy for breast cancer [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2024, 21(06): 571-579.
[3]	Wei Liu, Yunfeng Niu, Jie An. LINC01232 promotes malignant progression of triple negative breast cancer through miR-516a-5p/BCL9 axis [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(06): 330-338.
[4]	Jie Xu, Yajun Li, Yiwen Feng. Comparison of recent follow-up between laparoscopic D2 radical surgery and conventional radical surgery for advanced gastric cancer after SOX neoadjuvant chemotherapy [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 647-650.
[5]	Zhao Zhang, Chengyu Luo, Shuqi Zhang, Ping He, Xubin Li. Comparison of the effect, complication rate and recurrence rate of different operation methods in treating early breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(05): 494-497.
[6]	Jia Song, Bo Wang, Kailu Sun, Jiangfeng Shang, Danping Wu, Yi Zhao. Application of indocyanine green fluorescence imaging combined with methylene blue staining in sentinel lymph node biopsy of breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(05): 498-501.
[7]	Chengyan Luo, Lin Yuan, Shulin Zhou, Yi Jiang, Ting Chen, cong Wang, Wenjun Cheng. Laparoscopic interval debulking surgery in advanced ovarian cancer [J]. Chinese Journal of Laparoscopic Surgery(Electronic Edition), 2024, 17(06): 339-345.
[8]	Jiagang Han, Zhenjun Wang. The treatment strategies for obstructive left-sided colon cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(06): 450-458.
[9]	Yang Shi, Jianfeng Yu, Ke Cao, Zhiwei Zhai, Chunxiang Ye, Zhenjun Wang, Jiagang Han. Perioperative complication analysis of self-expanding metallic stents （sems） combined with neoadjuvant chemotherapy in the treatment of complete obstructive left-sided colon cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(06): 464-471.
[10]	Xuanhao Liang, Xiaorong Li, Liang Li, Changwei Lin. Efficacy and prognosis of colonic stenting combined with neoadjuvant chemotherapy for acute obstructive colorectal cancer： a Meta-analysis [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(06): 472-482.
[11]	Qi Liu, Shoukai Wang, Shuai Wang, Yuqing Su, Zhuang Ma, Haijun Chen, Pilei Si. Advances in research of intratumoral microbiome in breast cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(09): 841-845.
[12]	Junwei Cui, Huali Cai, Yibin Hu, Hui Hu. Clinical value of methylene blue combined with marker clip and hook-wire localization in evaluation of axillary lymph node metastasis after neoadjuvant chemotherapy for breast cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(07): 625-632.
[13]	Yuying Wang, Shiwei Liu, Rui Wang, Yaling Zng, Xihui Tu, Purong Zhang. Predictive factors for pathological complete response to neoadjuvant therapy for breast cancer in elderly patients [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(07): 641-646.
[14]	Shuai Wang, Zhiyuan Zhang, Yuqing Su, Wenwen Li, Shoukai Wang, Qi Liu, Wentao Li. Mendelian randomization and its application in breast cancer research [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(07): 671-676.
[15]	Mengting Zhang, Lamu Qiong, Zhen Se, Yiqun Li, Wangmu DeQing. Neoadjuvant chemotherapy for breast cancer patients in Tibet: a real-world study [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(05): 441-446.

Please choose a citation manager

Content to export